The global vaccine adjuvants market size was valued at USD 308.99 million in 2016 and is anticipated to grow with a CAGR of 10.6%. Rising prevalence of cervical cancer, infectious diseases such as Human Papillomavirus (HPV), HIV, tuberculosis, etc., and other fatal diseases are expected to boost the demand for adjuvants.
Besides, growing focus on the long-lasting effect of immunization against existing and emerging diseases is expected to boost demand for adjuvants. The importance of adjuvant research for the development of these products has increased significantly due to the inadequate immunogenicity of innovative vaccine antigens. Moreover, the increasing use of recombinant and synthetic vaccines is expected to accelerate the growth of this market in the coming years.
Major players are engaged in the discovery and development of new adjuvants to treat fatal diseases. Products under clinical trials include AS01, ISCOM & ISCOMMATRIX, and AS02, and the presence of these pipeline drugs is estimated to further boost the market.
The U.S. is a developed country with a huge population and a large number of travelers visit the country, which increases the need for immunization for the safety of the local population. Also, a rise in favorable government initiatives for immunization of people against serious diseases is anticipated to boost the market. For instance, the National Institute of Allergy and Infectious Diseases initiated a program for advancements in adjuvants for human use.
Based on type, the vaccine adjuvants market is segmented into a pathogen, adjuvant emulsion, particulate, combination, and others. Among these, the particulate type held the largest market share in 2016, followed by adjuvant emulsion. This large share can be attributed to the presence of a wide range of products and greater efficiency against the diseases.
Particulate type includes adjuvants consisting of alum, virosomes, and cytokines. Alum is the most commonly used adjuvant consisting of aluminum salts. It is used in hepatitis B and HPV vaccines. Virosomes that are particles resembling noninfectious viruses are used as adjuvants in hepatitis A, Epaxal, and influenza vaccine Inflexal.
On the other hand, the pathogen type segment is expected to be the fastest-growing over the forecast period. Some pathogenic adjuvants tested include monophosphoryl lipid A. It is combined with alum to produce AS04 adjuvant used in an HPV-Cervarix.
Infectious diseases accounted for the largest share in the vaccine adjuvants market. This large share can be attributed to the gradually growing prevalence of infectious diseases, such as malaria, influenza, hepatitis A, B, & C, and others. Also, the presence of strong pipeline products for vaccine adjuvants related to infectious diseases is anticipated to fuel the market growth in the coming years. This includes CpG (TLR 9 agonist) vaccine adjuvant from InvivoGen. The product is in phase 3 of clinical trial and provides CD8 T cell-mediated immunity and Th1-type immunity.
Cancer is identified to be the fastest-growing application segment due to its high prevalence and ongoing R&D for targeted therapy for various types of cancers. Moreover, increasing the use of adjuvants, such as Cervarix, is further anticipated to fuel growth.
Based on the route of administration, adjuvants are categorized into oral, intradermal, intranasal, intramuscular, and others. The intramuscular segment accounted for the largest market share in 2016 due to better immune specificity. These include vaccines for HPV, influenza, meningitis, etc. The efficacy of vaccines depends on the route of administration. For instance, alum salts, which are the most widely used parenteral adjuvants, are ineffective when administered by the oral or nasal route.
On the other hand, the intradermal route is expected to be the fastest-growing segment due to longer absorption time and duration of action as compared to other routes, which increases the demand for vaccines administered through this route. Some adjuvants, such as TLR3-Ligand Poly (I:C), induce mucosal antibody responses and protect against genital HSV-2 infection when administered intradermally.
North America held the largest market share in 2016 followed by Europe. The factors contributing to the growth of the vaccine adjuvants market in the North American region are a rise in investments for R&D of new therapeutics and an increase in fatal epidemic diseases. Thus, leading to the need for immunization against acute and chronic diseases. Also, the local presence of key market players in the U.S. increases the penetration of products. For instance, Adjuvance Technologies, Inc. has developed a portfolio of adjuvants targeted toward the treatment of various diseases.
Asia Pacific was estimated to be the fastest-growing market due to the continuously improving healthcare facilities, including the availability of medicines, coupled with rising R&D funding to meet the huge unmet demands. This is expected to increase the revenue share over the forecast period.
Some of the key participants in the market are GlaxoSmithKline plc.; Novavax, Inc.; Adjuvance Technologies, Inc.; SPI Pharma.; Agenus, Inc.; CSL Limited; InvivoGen; and Brenntag Biosector.
These market players are focusing on expanding their businesses in developing regions to increase their market share. Furthermore, they are adopting strategies such as collaborations, mergers & acquisitions, and new product development. For instance, in July 2017, GSK collaborated with Exscientia to develop new drugs.
Attribute |
Details |
The base year for estimation |
2016 |
Actual estimates/Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Market representation |
Revenue in USD Million & CAGR from 2016 to 2025 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, & MEA |
Country scope |
U.S., Canada, UK, Germany, Japan, China, Brazil, South Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research, Inc. has segmented the vaccine adjuvants market based on type, application, route of administration, and region:
Product Type Outlook (Revenue, USD Million; 2014 - 2025)
Pathogen
Adjuvant Emulsion
Particulate
Combination
Others
Application Outlook (Revenue, USD Million; 2014 - 2025)
Infectious Disease
Cancer
Others
Administration Type Outlook (Revenue, USD Million; 2014 - 2025)
Oral
Intradermal
Intranasal
Intramuscular
Others
Regional Outlook (Revenue, USD Million; 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
UK
Asia Pacific
China
Japan
Latin America
Brazil
MEA
South Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.